Figure 1.
Two Kaplan-Meier survival plots comparing treatment with atezolizumab plus EP (solid orange line) versus EP alone (dashed blue line). Panel A (top) shows overall survival over 48 months, with both lines appearing similar and showing a hazard ratio of 1.13 (95% CI, 0.56–2.28) and p=0.72. Panel B (bottom) shows progression-free survival over 24 months, also with overlapping lines and a hazard ratio of 1.33 (95% CI, 0.69–2.56) and p=0.35. The y-axis indicates probability of survival (0%–100%) and the x-axis indicates time in months.

(A) Kaplan–Meier plot of progression-free survival comparing the addition of atezolizumab to etoposide and platinum (EP) versus EP alone. The hazard ratio (HR) is 1.33 (95% CI, 0.69-2.56), with a P-value of .35. (B) Kaplan–Meier plot of overall survival comparing the addition of atezolizumab to EP versus EP alone. The HR is 1.13 (95% CI, 0.56-2.28), with a P-value of .72.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close